News

The deal included a total upfront consideration of $81 million, including a cash payment of approximately $65 million.

Faricimab is already approved in the EU and UK for neovascular age-related macular degeneration and diabetic macular edema.

Following the MAA in Europe, Altos Biologics plans to pursue approval in target markets including Korea

The company expects approval from the EMA by 2025.

From amniotic membrane grafting to neurotization.

Faricimab is already approved in the EU and UK for neovascular age-related macular degeneration and diabetic macular oedema

Apellis plans to seek re-examination, with a final opinion expected in fourth quarter of 2024.

The drug is a biosimilar for aflibercept 2 mg (Eylea)

Repeated 0.1-ml intravireal injections of lampalizumab, antigen-binding fragment of a humanized monoclonal antibody that inhibits complement factor D, seem to be associated with a low risk of elevated IOP

During interview earlier this year, we asked leaders in the retina field would tell residents and medical students as they train for the next decades in retinal care. Here's what 2 of them had to say.

Plasma emission for blepharitis, meibomian gland dysfunction, and dry eye disease.

Apellis will seek re-examination from the CHMP following the opinion

Ashley Brissette, MD, MSc, FRCSC, team ophthalmologist for the New York Rangers sat down to talk about eye injuries in hockey and other professional sports, as well as advancements in prevention and treatment for the players.

The retrospective cohort study by a team of researchers in China included 58 cataract eyes of 54 patients with corneal astigmatism who underwent phacoemulsification and rotationally asymmetric multifocal intraocular lens implantation. Patients were treated with either an opposite clear corneal incision or a single clear corneal incision.

We asked what leaders in the retina field would tell residents and medical students as they train for the next decades in retinal care. Here's what 2 of them had to say.

Management of neovascular glaucoma focuses on decreasing retinal ischemia through panretinal photocoagulation and the injection of anti-VEGF agents

A preview of presentations from 4D Molecular Therapeutics and Adverum Biotechnologies

The ASRS annual meeting will take place in Stockholm, Sweden on July 16-20, 2024. Several major updates are already anticipated at the event.

From AI tools and early diagnoses to advancing image rendering and predicting overall health, retinal imaging is reaching new heights.

Prevent Blindness is offering educational resources and will partner with OCuSOFT Inc. in support of Dry Eye Awareness Month in July.

The ASRS annual meeting will take place in Stockholm, Sweden on July 16-20, 2024. Several major updates are already anticipated at the event.

The award, supported by Oculis, will recognize outstanding contributions to retina research and will grant €30,000 for research support, and an additional €5,000 directly to the candidate.

The YOSEMITE/RHINE studies measured changes in the BCVA and CST from baseline to years 1 and 2

Presenters from around the world converge on the Pacific Northwest to highlight innovation.

The prize, presented by EURETINA and supported by Oculis, will recognise outstanding contributions to retina research

Fewer faricimab injections needed

4D-175 will be evaluated in the GAZE clinical trial, an upcoming phase 1, open-label trial.